The CAS has started hearings in the case of figure skater Valieva

USA Today reporter Christina Brennan reported that the Court of Arbitration for Sport (CAS) has begun hearings into a Russian figure skater’s doping case. Kamila Valieva.

The appeals of the Russian Anti-Doping Agency (RUSADA), the International Skating Union (ISU) and the World Anti-Doping Agency (WADA) against the decision of the Russian Anti-Doping Agency (RUSADA) in the case of athlete were previously grouped into one procedure. The CAS closed hearings will take place on September 26, 27, 28 and 29 (as applicable). Valieva, 17, is expected to participate in the hearing via video link.

“The hearings into the Kamila Valieva doping case are now taking place on the third floor of the Court of Arbitration for Sport building,” Brennan wrote on the social network.

Valieva at the 2022 Olympic Games in Beijing helped the Russian team win gold in the team competition. Before the personal tournament, it became known that the banned drug trimetazidine was found during the doping test of the figure skater of the Russian championship. In this regard, the International Olympic Committee (IOC) declared the results of the Olympic team tournament preliminary and postponed the award ceremony to the winners of the competition until the investigation into the matter is completed. The CAS admitted the Russian to the individual competitions of the Games, where she took fourth place.

In January, it became known that the anti-doping disciplinary committee of the Russian Anti-Doping Agency (DAK RUSADA) canceled Valieva’s result at the 2022 Russian Championship and concluded that the skater committed a violation of anti-doping rules, but it was “not her fault or negligence. Subsequently, RUSADA, WADA and ISU appealed the decision of RUSADA’s CAD to CAS. WADA demands that the Russian be suspended for four years.

Source : MatchTV

Related articles

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share article

Latest articles

Newsletter

Subscribe to stay updated.